The study is a pilot study designed to generate preliminary data regarding the cost of partial meniscectomy using NanoScope versus conventional arthroscopy in a traditional operating room (OR) setting

开始日期2024-11-01

申办/合作机构

Arthrex, Inc.

NCT06500364 / Not yet recruiting临床4期IIT

Knotless Implants as An Alternative for Capsular Closure in Primary Hip Arthroscopy: A Prospective, Multi-Center Study

The purpose of this research is to see if the Arthrex LoopLocTM device is better for capsular closure during hip arthroscopy than other treatments available.
The hip capsule is the tissue that surrounds your hip joint. It stabilizes and supports your hip joint. During hip arthroscopy, this tissue must be cut through in order to perform the hip arthroscopy. Once the hip arthroscopy is completed, the surgeon might repair the capsule. Current ways of repairing the capsule include knotted suture that might irritate structures around the hip, leading to the possible formation of scar tissue and pain. The Arthrex LoopLocTM device is knotless and may lower the presence of irritation and scar tissue around the hip after surgery and might lead to better outcomes.
Therefore, researchers will compare patients who had the LoopLocTM device used to close their hip capsule during surgery to those who did not have the device used, to see if there is a difference in their outcomes following surgery.

开始日期2024-08-01

申办/合作机构

American Hip Institute LLC初创企业

[+1]

NCT05765266 / RecruitingN/A

ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).

开始日期2024-05-13

申办/合作机构

Arthrex, Inc.

100 项与 Arthrex, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Arthrex, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Arthrex, Inc. 相关的文献（医药）

2024-12-01·AMERICAN JOURNAL OF SPORTS MEDICINE

Circumferential Labral Reconstruction With Knotless All-Suture Anchors Restores Hip Distractive Stability: A Cadaveric Biomechanical Analysis

Article

作者: Domb, Benjamin G. ; Smith, Benjamin L. ; Lall, Ajay C. ; Kahana-Rojkind, Ady H. ; Khoury, Anthony N. ; Wijdicks, Coen A.

Background::

The essential component of managing femoroacetabular impingement involves restoration of the original labral function. Circumferential labral reconstruction (CLR) has shown positive results. However, biomechanical studies of CLR are limited and have not established the efficacy of the modern knotless all-suture anchor (ASA) pull-through technique.

Hypotheses::

(1) CLR with knotless ASA fixation will restore native labral suction seal biomechanics; (2) tensioning the ASA to a high-tension state will increase the peak distractive force.

Study Design::

Controlled laboratory study.

Methods::

Eight fresh-frozen human cadaveric hips were dissected free of all soft tissue except the native labrum and transverse acetabular ligament. On an electromechanical testing system, the hips were compressively loaded to 250 N to initiate a suction seal and distracted at a rate of 10 mm/s until rupture of the suction seal. Hips were tested in 4 states: intact labrum, full labral removal, knotless CLR with moderate anchor tension, and CLR with high anchor tension. Peak distractive force (in newtons) was compared using repeated measures analysis of variance ( P < .05). Acetabular bevel angles (θ) were measured at labral clockface positions outside the transverse acetabular ligament using a 3-dimensional digitizer stylus after rim preparation. Linear regression plots compared θ and peak distractive force in the CLR state.

Results::

Peak force values were 138.5 ± 13.6 N (mean ± SE) for the intact labrum, 18.4 ± 2.79 N for labral excision, 95.4 ± 23.3 N for moderate-tension CLR, and 126.2 ± 27.3 N for high-tension CLR. Significant differences were observed only when full labral removal was compared with the other conditions: intact ( P < .001), moderate-tension CLR ( P = .016), and high-tension CLR ( P = .002). Steeper acetabular bevel angles (smaller θ) were correlated with greater suction seal restoration ( P < .05).

Conclusion::

CLR restored distractive stability on average to 82.0% of the intact value after labral deficiency. Retensioning did not significantly increase peak distractive forces.

Clinical Relevance::

These findings provide biomechanical validation supporting CLR using knotless ASAs in an effort to minimize volumetric bone loss and provide other surgical advantages. The prepared rim's bevel angle may be an important variable to optimize for improved suction seal restoration.

2024-11-01·JOURNAL OF HAND SURGERY-AMERICAN VOLUME

Over-the-Top Foveal Triangular Fibrocartilage Complex Repair

Review

作者: Rozenits, Andreas ; Dittman, Lauren E. ; Dittman, Lauren E ; Kakar, Sanjeev ; Kalapos, Robert

There are many techniques that address triangular fibrocartilage complex foveal injuries, which are typically performed with an outside to inside technique. In this article, we describe an inside to outside triangular fibrocartilage complex repair technique that may result in more accurate suture passage and mitigate the risk of fracture from ulna tunnels.

2024-11-01·Orthopaedic Journal of Sports Medicine

All-Suture Anchor Onlay Fixation for Medial Patellofemoral Ligament Reconstruction: A Biomechanical Comparison of Fixation Constructs

Article

作者: Smith, Benjamin L. ; Hauck, Oliver L. ; Bedi, Asheesh ; Riboh, Jonathan C. ; Wijdicks, Coen A.

Background::

The use of all-suture anchors (ASAs) for onlay patellar and femoral fixation of medial patellofemoral ligament (MPFL) grafts may provide clinical benefit, particularly in the small or pediatric knee; however, biomechanical data supporting the use of ASAs are lacking.

Purpose/Hypothesis::

The purpose of this study was to compare ASAs to larger interference implants for MPFL reconstruction in a time-zero biomechanical model. It was hypothesized that ASAs would have comparable cyclic elongation to interference fixation and would exceed published biomechanical values for the native human MPFL.

Study Design::

Controlled laboratory study.

Methods::

Eighteen fresh-frozen porcine patellas and femurs were divided into equal groups (n = 9 per group) for MPFL reconstructions. Patellar fixation utilized two 3.9-mm interference suture anchors (ISAs) or two 2.6-mm ASAs, while femoral fixation utilized one 6×20-mm interference screw (IS) or one 2.6-mm ASA. Human gracilis tendon grafts were used. Specimens were dynamically loaded for 100 cycles each in sequential 5- to 30-N (phase 1) and 5- to 50-N (phase 2) blocks at 1 Hz followed by load-to-failure testing at 305 mm/min.

Results::

No differences were found in cyclic elongation after phase 1 and phase 2 loading between ASA and interference implants on either the femoral or patellar side. On the femur, IS had significantly greater ultimate stiffness (54.2 vs 46.1 N/mm; P < .001) and ultimate load (366 vs 278 N; P = .019) compared to ASA. On the patella, ISAs had significantly greater ultimate stiffness (70.5 vs 53.1 N/mm; P < .001) but a significantly lower ultimate load (244 vs 307 N; P = .014) compared to ASAs. All groups significantly exceeded the published physiological values for native human MPFL stiffness and failure load.

Conclusion::

ASA onlay fixation had comparable cyclic elongation to that of interference fixation for femoral and patellar MPFL reconstruction. Although differences in ultimate stiffness and ultimate load were noted between implants, all of the values exceeded published values for the human MPFL.

Clinical Relevance::

This biomechanical study presents ASA cortical onlay fixation as a viable option for MPFL reconstruction. ASAs require less bone removal, potentially reducing the risk of patellar fracture and minimizing fixation complexity in the setting of open femoral growth plates. Future clinical studies will provide insight into successful tendon-to-bone healing, failure rates, and near- and long-term patient-reported outcomes.

项与 Arthrex, Inc. 相关的新闻（医药）

2024-08-21

·Business Wire

Bioactive Glass Business Analysis Report 2024: Multifunctional Bioactive Glass Rises in Popularity, Enhanced Biocompatibility and Efficacy Drive Adoption of Bioactive Glass Compositions - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Bioactive Glass - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Bioactive Glass is estimated at US$1.0 Billion in 2023 and is projected to reach US$3.1 Billion by 2030, growing at a CAGR of 17.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the bioactive glass market is driven by several factors, including technological innovations, increasing clinical acceptance, and expanding applications in the medical field. The continuous improvement in glass formulations and processing techniques has resulted in products that offer better performance and greater versatility, catering to a broader range of medical procedures. Clinical studies validating the efficacy and benefits of bioactive glass in tissue regeneration and infection control have bolstered its adoption among healthcare providers. Additionally, there is a growing trend of personalized medicine where materials like bioactive glass are used to develop customized solutions for individual patients, further propelling market growth. Economic factors, such as the rising healthcare expenditure globally and the increasing investment in biomedical research, also play significant roles in the expansion of this market. These elements collectively ensure that the demand for bioactive glass remains robust, reflecting its critical role in advancing medical treatments and improving patient outcomes. Key Insights: Market Growth: Understand the significant growth trajectory of the Silicate-based Glass segment, which is expected to reach US$1.6 Billion by 2030 with a CAGR of a 18.0%. The Phosphate-based Glass segment is also set to grow at 17.0% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $268.4 Million in 2023, and China, forecasted to grow at an impressive 16.2% CAGR to reach $474.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Why You Should Buy This Report: Detailed Market Analysis: Access a thorough analysis of the Global Bioactive Glass Market, covering all major geographic regions and market segments. Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies. Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Bioactive Glass Market. Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as Arthrex, Inc, BioMin Technologies Limited, Bonalive Biomaterials Ltd, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Questions Answered: How is the Global Bioactive Glass Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Key Attributes: Report Attribute Details No. of Pages 177 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $1 Billion Forecasted Market Value (USD) by 2030 $3.1 Billion Compound Annual Growth Rate 17.3% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Global Economic Update Bioactive Glass - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Increasing Use in Bone Regeneration Bodes Well for Market Growth Expanding Use in dental Fields Drive Market Growth Enhanced Biocompatibility and Efficacy Drive Adoption of Bioactive Glass Compositions Growing Geriatric Population and Prevalence of Orthopedic and Dental Disorders Bioactive Glasses Make Their Mark in Wound Healing Applications Shifts in Healthcare Spending Towards Advanced Biomedical Materials Multifunctional Bioactive Glass Rises in Popularity FOCUS ON SELECT PLAYERS (Total 39 Featured) Arthrex, Inc BioMin Technologies Limited Bonalive Biomaterials Ltd DePuy Synthes LASAK s.r.o. Matexcel Mo-Sci Corporation NanoFUSE Biologics LLC Noraker NovaBone Products LLC Schott AG Stryker Corporation Synergy Biomedical, LLC SynThera Biomedical Pvt. Ltd Vedayukt India Private Limited For more information about this report visit https://www.researchandmarkets.com/r/fzavs4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

2024-04-19

·PRNewswire

Arthrex Wins Both Gold and Silver Medals at 2024 Edison Awards

NAPLES, Fla., April 19, 2024 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. The MIS FiberTak® Achilles SpeedBridge™ Repair Implant System with Knotless Rip-Stop won Gold in the Surgical Innovations category. The innovative repair implant system and technique provides a minimally invasive approach for insertional Achilles tendinopathy. Continue Reading "This product, along with our other innovations, will prove to be a true benefit to patients and surgeons." Post this The MIS FiberTak® Achilles SpeedBridge™ Repair Implant System with Knotless Rip-Stop won Gold in the Surgical Innovations category. The innovative repair implant system and technique provides a minimally invasive approach for insertional Achilles tendinopathy. The SutureLoc™ implant, the first knotless, all-suture retensionable anchor designed specifically for arthroscopic meniscal root repair, took home the Silver award in the Orthopedic & Musculoskeletal Solutions category. “The team is really pleased to be recognized with such a prestigious award to acknowledge this important, innovative product specifically designed to preserve the meniscus,” said Product Manager, Knee Ligament Julia Cuny. “[The SutureLoc™ implant is] a complicated anchor to produce and it provides an entirely new mechanism that we developed just for this implant. It was truly a team effort with over 20 teams contributing to the development.” “This award is validation for the effort of the Extremities and Trauma Soft Tissue team in their drive to win the Achilles midsubstance tear market,” said Arthrex Senior Director, Product Management Pete Denove. “[The MIS FiberTak® Achilles SpeedBridge™ Repair Implant System with Knotless Rip-Stop], along with our other innovations, will prove to be a true benefit to patients and surgeons.”

2024-04-16

·PRNewswire

PowerHeal™ Revolutionizes Wound Care with Introduction of World's First and Only Bioelectric Bandage for Over-The-Counter Use

Innovative Healing Solution Sets New Standard in Consumer Wound Care PHOENIX, April 16, 2024 /PRNewswire/ -- Vomaris, a pioneer in bioelectric wound care technology, announces the launch of its FDA-cleared PowerHeal™ bioelectric bandage for over-the-counter (OTC) use, marking a significant advancement in consumer wound care. Unlike traditional wound care products, PowerHeal's one-of-a-kind bioelectric bandage represents a transformative leap, employing advanced technology to accelerate healing and minimize infection risk with unparalleled efficacy. Continue Reading "PowerHeal is proud to bring medical-grade wound care technology directly into the hands of consumers," said Michael Nagel, President & CEO of Vomaris Innovations, Inc. Post this Vomaris, a pioneer in bioelectric wound care technology, announces the launch of its FDA-cleared PowerHeal™ bandage for over-the-counter use, marking a significant advancement in consumer wound care. PowerHeal's bioelectric bandages are powered by patented microcell battery technology. Foundationally inspired by the body, PowerHeal technology mimics the electrical energy (known as Transepithelial Potential) that skin naturally creates and uses to heal itself. This revolutionary approach not only creates an optimal healing environment by maintaining moisture, it provides crucial antibacterial protection and introduces a new dimension of care, by generating electricity through moisture-activated microcell batteries that are embedded within PowerHeal bandages. PowerHeal does more than just cover a wound like traditional bandages, it helps heal it. Multiple published scientific and clinical studies have demonstrated its ability to accelerate the movement of healing cells across the wound surface and to effectively kill up to 99.99% of bacteria without the use of antibiotics, to help heal wounds by 2-3 times faster. "PowerHeal is proud to bring medical-grade wound care technology directly into the hands of consumers," said Michael Nagel, President & CEO of Vomaris Innovations, Inc. "Our bioelectric products are designed to empower people to take charge of their healing by delivering fast, safe, and effective advanced wound care at home." This innovation is a game-changer for individuals facing a spectrum of acute and chronic wounds, including cuts, scrapes, large abrasions like road rash and turf burn, burn wounds, surgical incisions, and challenging wounds such as those from diabetes or ulcers resulting from venous disease. With approximately 6.5 million Americans treated for chronic wounds each year1, an estimated 3.6 million people suffering from diabetes-related wounds2, and surgical site infections affecting 1.5 million people each year in the US alone3, the need for effective advanced wound care is significant. Now more than ever before, patients are empowered consumers that are taking control over how, when, and in what manner they receive care. The global advanced wound care market is valued at $14 billion in 2024, and is predicted to surpass $45 billion by 2032,4 largely driven by diabetes, obesity, and the aging population. PowerHeal exists not only to further empower the 10 million plus patients with acute and chronic wounds, but also to give all wound care consumers the ability to take charge of their healing. "With nearly a decade of success in the prescription surgical and wound care markets, PowerHeal's technology has treated over one million wounds to-date," emphasized Mary Maijer, Chief Commercial Officer of Vomaris Innovations, Inc. "Bringing this clinically-proven product to consumers is in direct response to the expressed need to make well-substantiated wound care products more broadly available." Consumers can now access PowerHeal's bioelectric bandages at powerhealwounds.com and on Amazon, offering convenient at-home wound care. With a variety of sizes, and no-adhesive and adhesive options available, ranging from $5 to $14 per bandage, individuals can find the right fit for their needs, whether addressing acute injuries or managing chronic conditions. ABOUT PowerHeal™: PowerHeal is the world's only bioelectric bandage that is FDA-cleared for OTC use. The microcell battery design supports your skin's natural recovery capacity to heal wounds 2 - 3 times faster — so you can take charge of your healing and power on. For more information about PowerHeal bioelectric bandage, visit powerhealwounds.com, and follow PowerHeal on Instagram and Facebook. ABOUT VOMARIS Vomaris Innovations, Inc. () is a privately held medical device company based in Arizona, specializing in bioelectric technology that is redefining infection control and wound healing. Vomaris' patented microcell battery technology powers antimicrobial products for the advanced wound and incisional care markets and has been validated in 28 peer-reviewed publications to-date. It is FDA cleared and commercially available for over-the-counter use under the brand name PowerHeal and prescription use under the brand names Procellera® and JumpStart® Antibacterial Wound Dressings. Vomaris, and Procellera are registered trademarks of Vomaris Innovations, Inc. JumpStart is a registered trademark of Arthrex, Inc. PRESS CONTACT: Demonstrate for PowerHeal [email protected] 415.400.4214 1 Nussbaum S, et al. (2018). "An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds." Value Health, 27-32. MedMarket Diligence, LLC. (2018). "Billions in Global Wound Product Sales, Yet Chronic Wounds Remain a Chronic Problem, Based on New Research from MedMarket Diligence." PR.com, 1-2. Wound Reach Foundation. (2013-2019). "The Challenge: When Was the Last Time You Said 'Ouch!'?" 2 Burgess JL, Wyant WA, Abdo Abujamra B, Kirsner RS, Jozic I. (2021, October 8). "Diabetic Wound-Healing Science." Medicina (Kaunas), 57(10), 1072. doi: 10.3390/medicina57101072. PMID: 34684109; PMCID: PMC8539411. 3 Michael P. (2017). "2017 HICPAC-CDC Guideline for Prevention of Surgical Site Infection: What the Infection Preventionist Needs to Know." Prevention in Action. 4 Advanced Wound Care Market (By Type: Infection Management, Exudate Management, Active Wound Care, Therapy Devices; By Application: Chronic Wounds, Acute Wounds; By End User: Hospitals, Specialty Clinics, Home Healthcare, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032 SOURCE Vomaris